Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NanoViricides (NNVC)

NanoViricides Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:NNVC
DateTimeSourceHeadlineSymbolCompany
02/05/202415:07InvestorsHub NewsWireNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected SoonAMEX:NNVCNanoViricides Inc
16/02/202421:53Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
14/02/202421:55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:NNVCNanoViricides Inc
19/01/202421:44Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
04/12/202321:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:NNVCNanoViricides Inc
13/10/202321:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:NNVCNanoViricides Inc
28/09/202321:44Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405AMEX:NNVCNanoViricides Inc
01/09/202321:46Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
06/07/202316:16InvestorsHub NewsWireClinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical NeedsAMEX:NNVCNanoViricides Inc
25/05/202321:34Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NNVCNanoViricides Inc
08/05/202322:20Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)AMEX:NNVCNanoViricides Inc
04/05/202311:45GlobeNewswire Inc.NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York CityAMEX:NNVCNanoViricides Inc
14/02/202322:24Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
13/02/202322:02Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NNVCNanoViricides Inc
23/12/202211:04Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)AMEX:NNVCNanoViricides Inc
15/11/202221:32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:NNVCNanoViricides Inc
04/11/202220:33Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)AMEX:NNVCNanoViricides Inc
13/10/202222:13Edgar (US Regulatory)Annual Report (10-k)AMEX:NNVCNanoViricides Inc
29/09/202217:20Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)AMEX:NNVCNanoViricides Inc
10/08/202223:52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:NNVCNanoViricides Inc
16/05/202221:55Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
15/11/202121:55Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
15/11/202112:09InvestorsHub NewsWireNanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2AMEX:NNVCNanoViricides Inc
12/10/202111:16Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:NNVCNanoViricides Inc
11/10/202111:49InvestorsHub NewsWireNanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus ActivityAMEX:NNVCNanoViricides Inc
05/10/202111:45PR Newswire (US)NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap ConferenceAMEX:NNVCNanoViricides Inc
05/10/202111:45PR Newswire (US)NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap ConferenceAMEX:NNVCNanoViricides Inc
28/09/202121:32Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)AMEX:NNVCNanoViricides Inc
22/09/202111:48InvestorsHub NewsWireSignificantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral DrugAMEX:NNVCNanoViricides Inc
22/09/202111:45PR Newswire (US)Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral DrugAMEX:NNVCNanoViricides Inc
 Showing the most relevant articles for your search:AMEX:NNVC